Association of HCT with overall mortality, unadjusted, and adjusted models with HCT modeled as a time-dependent covariate
| . | Unadjusted . | Adjusted∗ . | ||
|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | |
| All patients (N = 692) | 0.71 (0.57-0.88) | .002 | 0.85 (0.66-1.09) | .19 |
| Patients aged ≥65 y (n = 295) | 0.65 (0.46-0.90) | .01 | 0.79 (0.53-1.16) | .22 |
| Patients with augmented HCT-CI scores ≥4 (n = 353) | 0.63 (0.46-0.86) | .0004 | 0.84 (0.58-1.21) | .34 |
| Patients with ELN intermediate risk (n = 296) | 0.55 (0.40-0.77) | .0004 | 0.81 (0.55-1.17) | .26 |
| Patients with ELN adverse risk (n = 248) | 0.37 (0.25-0.54) | <.0001 | 0.58 (0.38-0.89) | .01 |
| Patients who achieved CR1 (n = 510) | 0.85 (0.67-1.09) | .20 | 0.96 (0.72-1.27) | .75 |
| Patients who did not achieve CR1 (n = 182) | 0.27 (0.15-0.51) | <.0001 | 0.45 (0.22-0.90) | .02 |
| . | Unadjusted . | Adjusted∗ . | ||
|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | |
| All patients (N = 692) | 0.71 (0.57-0.88) | .002 | 0.85 (0.66-1.09) | .19 |
| Patients aged ≥65 y (n = 295) | 0.65 (0.46-0.90) | .01 | 0.79 (0.53-1.16) | .22 |
| Patients with augmented HCT-CI scores ≥4 (n = 353) | 0.63 (0.46-0.86) | .0004 | 0.84 (0.58-1.21) | .34 |
| Patients with ELN intermediate risk (n = 296) | 0.55 (0.40-0.77) | .0004 | 0.81 (0.55-1.17) | .26 |
| Patients with ELN adverse risk (n = 248) | 0.37 (0.25-0.54) | <.0001 | 0.58 (0.38-0.89) | .01 |
| Patients who achieved CR1 (n = 510) | 0.85 (0.67-1.09) | .20 | 0.96 (0.72-1.27) | .75 |
| Patients who did not achieve CR1 (n = 182) | 0.27 (0.15-0.51) | <.0001 | 0.45 (0.22-0.90) | .02 |
Adjusted for the augmented HCT-CI, age, ELN cytogenetic risk, relapsed/refractory AML at enrollment, posttreatment CR1 status, treatment intensity, sum PHQ-9, KPS, ADL, FACT-G, and 4-MWT (posttreatment CR1 status, sum PHQ-9, KPS, ADL, FACT-G, and 4-MWT modeled as time-dependent variables, with missing indicator to account for those without data).